Curr Gastroenterol Rep. Author manuscript; available in PMC 2011 Oct 1.
Published in final edited form as:
PMCID: PMC2965634
NIHMSID: NIHMS233209
Department of Internal Medicine, Division of Digestive Diseases, University of Oklahoma Health Sciences Center, 975 NE 10th Street, SL Young BRC West 1268B, Oklahoma City, OK 73104, USA
Shahid Umar, Department of Internal Medicine, Division of Digestive Diseases, University of Oklahoma Health Sciences Center, 975 NE 10th Street, SL Young BRC West 1268B, Oklahoma City, OK 73104, USA;
Self-renewal in the intestinal epithelia is fueled by a population of undifferentiated intestinal stem cells (ISCs) that give rise to daughter or progenitor cells, which can subsequently differentiate into the mature cell types required for normal gut function. The cellular signals that regulate self-renewal are poorly understood and the factors that mediate the transition from a stem cell to a progenitor cell in the gut are unknown. Recent studies have suggested that ISCs are located either at the crypt base interspersed between the Paneth cells (eg, Lgr-5+ve cells) or at or near position 4 within the intestinal crypt (eg, DCAMKL-1 or Bmi-1+ve cells). This raises the possibility that distinct stem cell regions exist in the crypts and that ISC's state of activation will determine how the self-renewal is regulated in the intestinal tract.
Keywords: Intestinal stem cell (ISC), Self-renewal, Transit amplifying (TA) cell, Enterocytes, Paneth cells, Enteroendocrine cells, Goblet cells, Intestinal crypts, Inflammation, Radiation
The absorptive and protective functions of the gut are dependent on an intact and functional intestinal epithelium. Homeostasis of the normal adult intestinal epithelium is maintained by continuous and rapid replacement of differentiated cells by replication of undifferentiated epithelial or transit cells located within the crypts and subsequent differentiation of their progeny during migration away from the zone of replication. This renewal process involves rapid and continuous proliferation of epithelial cells in the crypt base with subsequent migration of these cells along the crypt-villus axis. The process of epithelial cell renewal within the intestine appears to be entirely dependent upon a limited number of long-lived multipotent intestinal stem or progenitor cells. An intestinal stem cell (ISC), similar to stem cells of the mouse hematopoietic system and the hair follicle, may be broadly defined by at least two properties: the ability to maintain itself throughout long periods of time (ie, self-renewal) and the potential to generate all differentiated cell types including enterocytes, goblet cells, entero-endocrine cells, and Paneth cells (ie, multipotency). When stem cells divide, they are believed to undergo an asymmetric cell division into a new stem cell plus a committed daughter cell. The rapidly cycling daughter cells, also called transit amplifying (TA) cells, then undergo a limited number of cell divisions before terminally differentiating into a tissue mass. The regulatory mechanisms that control stem cell proliferation at baseline and in response to injury are just beginning to be explored. This review highlights recent discoveries and implications the ISC field may have on the regenerative processes in the digestive tract involved in health and disease.
The intestinal epithelium is the most vigorously self-renewing tissue of adult mammals [1]. It is specified from endoderm formed during gastrulation and remains as a stratified cuboidal epithelium until mid-gestation in most vertebrates [2]. During middle to late gestation, the basic tissue architecture of the intestine is established through epithelial-mesenchymal interactions. Induced by signals from mesoderm-derived mesenchyme, the endoderm-derived epithelium evaginates to form villi and intervillus regions. The intervillus regions consist of undifferentiated and actively dividing cells that eventually invaginate into the mucosa to form the crypt of Lieberkhn in the first few days after birth and continue to develop during the next several weeks in the rodent [3].
The small intestinal architecture consists of continuous villi and crypts (). The functional compartment of the epithelium contains differentiated cells no longer capable of dividing that have the features of mature epithelial cells. These differentiated epithelial cells populate the villi and can be categorized based on their function: enterocytes that function to absorb nutrients, goblet cells that secrete a protective mucus barrier and enteroendocrine cells that release gastrointestinal hormones (). Paneth cells that secrete antibacterial peptides on the other hand, reside at the base of the proliferative compartment [4]. The proliferative compartment contains undifferentiated and rapidly cycling cells that populate the crypts of Lieberkhn. The epithelium in this region is responsible for providing the tremendous cell turnover and the protective niche for the epithelial stem cell. As cells begin to differentiate, they migrate toward the lumen and are eventually shed, either from the tip of the intestinal villi or from the surface of the colonic epithelium. Therefore, the crypt is mainly a proliferative compartment, is monoclonal, and is maintained by multipotent stem cells whereas the villus represents the differentiated compartment and is polyclonal as it receives cells from multiple crypts [5].
Intestinal stem cell (ISC) compartments in the mammalian intestine. a The intestinal crypt-villus unit. ISCs reside at the base of the crypt, either in the +4 position counting from the bottom of the crypt (brown) directly above the Paneth cells (gray), or as crypt base columnar (CBC) cells (red) located between the Paneth cells, whereas transit-amplifying (TA) progenitor cells (yellow) can arise from self-renewing CBCs. Goblet cells and enterocytes are labeled purple and green, respectively. b Chemical and immunohistochemical detection of the four principal cell lineages of the small intestine: villus-associated absorptive cells (Fatty acid binding protein, stains the villi), Goblet cells (stained by periodic acid/Schiff), enteroendocrine cells (stained for synaptophysin, arrows), and Paneth cells (stained for lysozyme). c An enlarged view of a small intestinal crypt depicting two different stem cell regions; a quiescent stem cell zone (+4 position), and an active stem cell zone (+1 to +4 positions) scattered between the Paneth cells. The +4 label-retaining cells (LRCs) are normally maintained in a quiescent state through direct interaction with and signals generated from the niche, such as pericryptal fibroblast/myofibroblasts and adjacent enteroendocrine cells within the +4 region. CBCs, continuously activated by signals generated from stromal cells at the crypt base, are responsible for most of the regenerative capacity of the intestine under homeostatic conditions. A gradient of BMP signaling, known to inhibit proliferation, is established along the crypt-villus axis, with relatively high activity throughout the villus and correspondingly less activity within the crypt. An opposite gradient of Wnt signaling, providing an important proliferative stimulus, is highest at the crypt base and decreases toward the crypt-villus junction. (A, reproduced with permission from Dr. Hans Clevers, Hubrecht Institute-Royal Netherlands Academy of Arts and Sciences and the University Medical Center Utrecht, Utrecht, The Netherlands)
The well-compartmentalized structure of the small intestine is advantageous for analysis of developmental processes; however, study within this tissue has been limited by lack of a robust in vitro culture system for primary intestinal epithelial cells. Recently, studies with transgenic and knockout mice have shed light on molecular mechanisms underlying the fetal development of intestine as well as homeostatic epithelial regeneration in the adult. Through these studies, several signaling pathways such as the Wnt, bone morphogenic protein (BMP), phosphatidyl inositol (3,4,5) kinase (PI3K), and Notch cascades have been revealed to play critical roles in regulating proliferation and controlling ISC self-renewal and differentiation in normal tissue.
Stem cells are defined by their ability to self-renew and to give rise to mature cell types to maintain the integrity of the intestinal epithelium. Given the importance of stem cells to body tissues, it has long been postulated that stem cells should divide infrequently to prevent the acquisition of errors during DNA replication and to preserve their long-term proliferation potential. In humans, however, billions of cells are lost on a daily basis and therefore must be replenished for survival. Moreover, human tissues occasionally face traumatic injuries. The injured tissues have to be repaired quickly through rapid stem cell division and differentiation to maintain a proper balance. Thus, an extraordinary mechanism of regulation at the stem cell level apparently exists to allow stem cells to divide sparingly, to maintain their long-term potency, and rapidly, to maintain tissue homeostasis and repair injured tissues. Small intestinal epithelial lining is regenerated every 4 to 5 days. Either four to six [6] or one ISC [7] are present in small intestinal crypts, which cycle slowly (2430 h) and give rise to rapidly cycling TA cells by asymmetric division [8]. The TA cells move up the crypt and undergo differentiation into either absorptive (enterocytes) or secretory lineages (mucous, enteroendocrine, Paneth cells), which then move upward into the villus [9] (). Paneth cells, however, migrate downward to the base of the crypts [4]. Enterocytes are the dominant lineage (90% of total cells), goblet cells comprise 8% to 10% and enteroendocrine cells comprise about 1% of the epithelium. Stem cells in animal tissues are often located and controlled by special tissue microenvironments known as niches. A stem cell niche can be defined as a specific location in a tissue where stem cells can reside for an indefinite period of time and produce progeny cells while self-renewing. This niche is made up of and influenced by nearby proliferating and differentiating epithelial cells as well as by surrounding mesenchymal cells. Although separated from the epithelial cells by the basement membrane, these mesenchymal cells (ie, blood vessels, intraepithelial lymphocytes, and fibroblasts/myofibroblasts) together with the extracellular matrix, promote the epithelial-mesenchymal crosstalk required to maintain the stem cell niche. Epithelial-mesenchymal interactions enable specification of epithelial stem cells during development [10], but the requirement and nature of these communications in adult stem cells remain to be characterized. Excessive stem cell production can result in cancer; thus, maintaining a balance of stem cell quiescence and activity is a hallmark of a functional niche [11]. We have just begun to understand which niche signals regulate self-renewal and maintain the balance between self-renewal and differentiation of ISCs. An increasing number of signaling pathways, including Wnt, BMP, Hedgehog, and Notch, may play important roles in this regard, as discussed in the following section.
Wnt proteins form a family of highly conserved secreted signaling molecules that are capable of signaling both in an autocrine and paracrine fashion. Wnt induces its biologic effects by binding to either the seven-span transmembrane protein Frizzled (Fz) or the single-span low-density lipoprotein receptor-related protein (LRP). Wnt-mediated signaling results in increased stability of -catenin in the cytoplasm, and its interaction with the T-cell factor 4 (Tcf-4) transcription factor within the nucleus. Under normal conditions, -catenin forms a complex of proteins containing adenomatosis polyposis coli (APC), axin, and glycogen synthase kinase-3 (GSK-3) and its levels are tightly controlled through ubiquitin-mediated proteasomal degradation. Wnt factors inhibit the -catenin-APC complex. Hence, -catenin is stabilized and interacts with nuclear Tcf-4 to drive the transcription of specific target genes. Initial studies demonstrated that active Wnt signaling was found in intervillus regions and was thought to inhibit differentiation and stimulate proliferation, as indicated by experiments in which inhibition of Wnt signaling by Tcf-4 disruption halted the proliferation of endoderm and depleted endodermal stem/progenitor cells [12]. These experiments also showed that proliferative cells in the intervillus region were replaced by mature enterocytes usually seen in the villus [12]. However, recent findings indicate that Wnt signaling within the developing intestine may be more complex. In fact, Wnt activity was found exclusively within the villus epithelium from embryonic day 16 (E16) to postnatal day 2 (P2) and was not seen within the intervillus region until P2. However, by E14, villus and intervillus regions displayed unique genetic signatures and by E17.5, proliferative cells were restricted to intervillus regions. In addition, although nuclear -catenin and c-MYC expression corresponded to the villus cells with Wnt activity, other known Wnt target genes and pathway components such as CD44, CyclinD1, and Tcf-4 were present within the intervillus region [13]. These results suggest that Wnt signaling and proliferation may be uncoupled during early development and that perhaps Wnt-independent mechanisms drive early epithelial proliferation. Furthermore, Wnt signaling may play an important role in initial villus formation. Wnt signaling components are expressed by crypt epithelial cells and surrounding mesenchymal cells, which play an extremely important role in normal homeostasis [11, 14, 15] (). Wnt inhibitors, such as Dkk3, may be expressed in a graded manner along the crypt-villus axis, providing the balance between positive and negative regulators of this pathway [16].
Indian hedgehog (Ihh) is also expressed in the intervillus region, whereas its receptor, Patched, is expressed in the adjacent mesoderm [17]. Because Hedgehog inhibition compromises villus formation, this signal is thought to work as a morphogen within the intestine as in other tissues [18]. It remains unclear whether Ihh signaling is dependent on Wnt activation or is completely independent. More recently, Ihh was shown to regulate ISC self-renewal and differentiation [19]. Intestinal epithelial Ihh signals to the mesenchymal compartment to regulate formation and proliferation of mesenchymal cells, which in turn affects the epithelial proliferation and differentiation. These findings provide a basis for analyses of the role of the muscularis mucosae in ISC regulation. Indeed, expression of BMPs mainly in mesoderm-derived mesenchymal cells is regulated by Hedgehog signaling, and BMP signaling also plays a role in regulating morphogenesis during intestinal development [20]. Inhibition of BMP signaling by over-expression of its inhibitor, Noggin, or conditional inactivation of its receptor, BMPR1A, causes ectopic crypt formation, suggesting a role for BMP signaling in restricting crypt numbers [21].
A high level of Notch is expressed in the intestinal stem cells [11]. Four isoforms of the Notch receptor have been identified in mammals (Notch14) [22]. Notch activation is achieved through direct interaction with specific transmembrane ligands of the DSL (Delta/Serrate/Caenorhabditis elegans Lag-2) family, such as Delta-like (DLL) 1, 3, and 4 and Jagged 1-2 in mammals [23]. Notch-DSL ligand binding initiates proteolytic cleavage at both the extracellular and intracellular regions of the Notch receptor, leading to the release of Notch intracellular domain (NICD) [24]. Nuclear localization signals within the NICD direct its translocation, where it binds to and displaces a CSL transcriptional corepressor complex [25, 26]. Basic helix-loop-helix transcription factors of the Hairy/E(spl) (HES) and HES-related genes in vertebrates class are the best-characterized Notch targets [27]. Importantly, Notch transcriptional output depends greatly upon specific cell and tissue types because various events such as pathway crosstalk can affect the transcriptional regulation of tissue-specific differentiation, development, and cell-cycle regulation [28].
The Notch signal controls daughter cells differentiating into absorptive rather than secretory cells. Like Wnt signaling, the Notch pathway also plays a role in stem cell maintenance [28]. Components of the Notch pathway are chiefly expressed in the epithelium at the crypt base, in the stem cell region. Increasing Notch signaling through forced expression of NICD in newborn mouse results in increased cell proliferation in the stem cell compartment and also shows a severe reduction of all three secretory cell types [28]. Conversely, inhibition of the Notch signaling in the intestinal epithelium, either by deletion of the Hes1 gene, the CSL gene, the Notch1 and Notch2 genes, or through pharmacologic -secretase inhibitors, results in an excessive number of secretory cells [1, 29]. Although Notch signaling plays an important role in stem cell proliferation, the experimental results suggest that Notch signaling functions in the TA compartment controlling absorptive rather than secretory cell fate decisions in the intestinal epithelium.
In summary, among the four major signals characterized so far (Wnt, Notch, Hh, and BMP), Wnt signaling mainly functions in the crypt base to maintain stem cell proliferation and self-renewal; Notch signaling mainly functions in the TA compartment to control daughter cell fate determination; and the Hh-BMP signaling from the crypt or intervillus pocket delivers a long-range signal to inhibit the formation of crypts and promote the formation of villi.
The location, number, and behavior of ISCs within the base of the crypt have been characterized by numerous investigators using murine models [4], following chemoradiation [30], somatic mutation [31], chimeric breeding [32], and transgenic overexpression or ablation of specific regulatory genes [12, 20, 21, 33]. Interpretation of these data with respect to the precise position and behavior of ISC within the intestinal crypt continues to be debated [34, 35]. In the mouse small intestine, two types of stem cells have been identified [35]. One type is located below the +4 position in the stem cell zone and the other type is located at the +4 position from the crypt bottom. Cheng and Leblond [4] identified small cycling epithelial cells interspersed between the Paneth cells, or the so-called crypt base columnar (CBC) cells, using morphologic methods in mammalian intestine. Later, Bjerknes and Cheng [36] provided additional information on these specialized cells using elegant clonal marking techniques. These investigators postulated that the CBCs located within the stem cell zone of the crypt base might represent the actual ISC and that all the differentiated intestinal epithelial cell types develop from these CBCs [36]. An alternative hypothesis also suggested that the ISCs were actually located elsewhere at a position that averaged +4 from the bottom of the crypts, with the lowest three positions generally relegated to the terminally differentiated Paneth cells. Evidence supporting this hypothesis of the +4 stem cell model was provided by Potten [30]. These investigators, using the DNA-labeling reagents, bromodeoxyuridine or (3H)-thymidine, on radiation-sensitive, label-retaining cells (LRC) showed that the LRCs were located specifically at the +4 position in the intestinal crypt region, precisely at the origin of the migratory epithelial cell column.
One major obstacle in ISC biology has been the lack of definitive markers that identify ISCs. Reliable markers would allow for definitive identification of the stem cell population and would facilitate the ability to isolate and manipulate these cells in vitro. Numerous proteins are expressed in the crypt compartment but not in the villus, such as EphB2 [37], CD44 [38], and Hes1 [39]. Immunohistochemistry and in situ hybridization studies suggested that RNA binding protein Musashi-1 (Msi-1), involved in Notch signaling, is also expressed in the supra-Paneth cells as well as in CBC cells () [39, 40]. Members of BMP and Wnt signaling pathways (p-PTEN and p-AKT) localize to ISCs [20, 41]. In recent years, fluorescence-activated cell sorting has been used to identify side population (SP) cells in murine small intestine as a source of putative ISCs [42]. These SP cells were distinct from the hematopoietic stem cells and their progeny, based on the absence of surface markers for CD45, c-kit, and CD34. RNA prepared from CD45-negative intestinal SP cells were found to be enriched with Msi-1 [42]. The molecular features of the potential stem cell populations in SP faction were recently characterized [43]. Protein markers such as EphB2 [37], CD44 [38], Fgfr3 [44] and Sox9 [45] have a crypt-base expression pattern, but are not specific to ISCs. Analyses of various Wnt pathway components and their target genes have identified Sfrp5 [46] and Ascl2 [46] as possible ISC markers. Besides these, it was recently shown that telomerase reverse transcriptase (mTert), as identified in GFP transgenic mice, stains a few cells at cell position 4 [47]. None of these genes, however, encode for proteins that are amenable to cell-sorting procedures. Laser-capture microdissection method found numerous transcripts involved in c-myc signaling to be significantly expressed in putative ISC cells [48]. Immunohistochemistry studies showed that doublecortin and Ca2+/calmodulin-dependent kinase-like-1 (DCAMKL-1) and Mapk14 are expressed within the stem cell zones [49].
Proposed intestinal stem cell markers
Long-term DNA-label retention tentatively located stem cells at position +4 directly above Paneth cells [50]. Leucine-rich-repeat-containing G-protein-coupled receptor-5 (LGR5) expression was demonstrated in crypts of small intestines, but not in the villi by in situ hybridization [51]. LGR5 gene marked the slender cycling crypt base columnar (CBC) cells (), interspersed between Paneth cells [51]. LGR5 encodes an orphan G-protein-coupled receptor, characterized by a large leucine-rich extracellular domain [51], and is expressed in colorectal, ovarian, and hepatocellular carcinomas [51]. The CBC cells were positive for proliferation marker Ki67 and occasionally expressed M-phase marker phospho-histone H3 [51]. Adult mice irradiated with 1 to 10 Gy were analyzed for apoptosis after 6 h. Apoptosis was determined in +4 CBC cells and TA cells (located at position 515) [50]. Maximal apoptosis at +4 position was reached at 1 Gy, whereas 10 Gy was needed to measure apoptosis in CBC and TA cells, suggesting that LGR5 may be a marker for stem cells in small and large intestines [51]. Moreover, using genetic approaches, it was demonstrated that LGR5-positive CBCs are multipotent for all mature intestinal epithelial cell types, cycle every 24 h, and persist for 60 days [51]. Thus, even though questions remain regarding the functional role of LGR5 in the intestinal epithelia [52], loss of LGR5 may affect both crypt regeneration and neoplastic transformation.
In 2009, lineage-tracing studies of adult prominin-1 (also called CD133; a pentaspan transmembrane glycoprotein that localizes to membrane protrusions) showed that some prominin-1positive cells are located at the base of crypts in the small intestine, co-express LGR5, and can generate the entire intestinal epithelium, and therefore seem to be small intestinal stem cells as well [53]. Moreover, olfacto medin 4 (OLFM4), which was identified in a gene expression profile for LGR5-positive cells, was shown to be highly expressed in CBCs in the human small intestine and colon, and may therefore be a marker for human intestinal and colon stem cells [54]. Sangiorgi and Capecchi [55] characterized the progeny of crypt Bmi1-positive cells (; ) and argued in support of the +4 LRCs as a population of stem cells within the small intestine. Bmi1 encodes a chromatin remodeling protein of the polycomb group that has essential roles in self-renewal of hematopoietic and neural stem cells. Bmi1 seems to consistently mark long-lived cell clones (>12 months) populated by all intestinal lineages and serves as a specific marker of a cell population located at the +4 position of the crypt. Furthermore, ablation of Bmi1-positive cells by targeted expression of the diphtheria toxin depletes the epithelium of the genetically marked crypts (known as whole crypt units) [55]. Thus, expression of Bmi1 also identifies ISC candidates. In addition to LGR5 and prominin-1, other potential stem cell markers have been identified for which lineage tracing is not yet complete.
It was reported recently that DCAMKL-1, a microtubule-associated kinase expressed in post-mitotic neurons, is a novel putative ISC marker (; ) [56]. DCAMKL-1 was identified as a Gene Ontogeny-enriched transcript expressed in comparison with gastric epithelial progenitor and whole stomach libraries [49] and more recently in gastric stem cells [57]. Immunoreactive DCAMKL-1 cells were found at or near position +4, at a frequency of one cell per five crypts [56]. DCAMKL-1-positive CBC cells were also observed, but at much lower frequency [56]. More recently it was shown that the novel putative ISC marker DCAMKL-1 is predominantly expressed in quiescent cells in the lower two thirds of the small intestinal crypt epithelium and in occasional CBC cells [58]. In contrast, novel putative stem cell marker LGR5 is observed in rapidly cycling CBCs and in occasional crypt epithelial cells [58]. Functionally quiescent DCAMKL-1positive crypt epithelial cells retained BrdU label in a modified label-retention assay [58]. Importantly, it was demonstrated that DCAMKL-1 is a cell surface expression protein, and a specific antibody against the extracellular domain of DCAMKL-1 was used to isolate DCAMKL-1 positive cells from adult mouse small intestine by fluorescence-activated cell sorting [58]. DCAMKL-1positive cells were found to self-renew and form spheroids in suspension culture [58]. These spheroids formed glandular epithelial structures in the flanks of athymic nude mice, which expressed multiple markers of gut epithelial lineage [58]. Thus, DCAMKL-1 is a marker of quiescent ISCs and can be distinguished from the cycling stem/progenitor cells that are LGR5 positive. DCAMKL-1 did not co-localize with other key markers such as chromogranin A, pPTEN, pAKT, somatostatin, or secretin [58]. LGR5 identifies proliferative CBC and TA cells in the gut as evidenced by co-labeling with proliferating cell nuclear antigen. Thus, the original hypothesis of a +4 ISC [50] is likely accurate, and DCAMKL-1positive cells likely represent the elusive quiescent ISCs.
Restoration of normal epithelial architecture and function after intestinal injury induced by a variety of noxious agents (chemical, infectious, radiation, and inflammatory) is a multistep process that involves tight regulatory control of epithelial stem cell dynamics [59]. First, migration of adjacent epithelial cells over the wound reestablishes continuity of the epithelium. Stem cells divide to increase their numbers and to give rise to the more rapidly proliferating TA cells. The transit cell population then expands rapidly to form a regenerative crypt. A single surviving clonogenic crypt stem cell is sufficient to facilitate crypt regeneration. If the injury has completely destroyed some crypts, the surviving crypt stem cells can divide to increase their numbers, and subsequently restore sufficient numbers of crypts by crypt fission, to maintain epithelial homeostasis [59]. Whether this process involves recruitment of a quiescent stem cell population from within the crypt-villus axis or requires replenishment from the bone marrow remains to be determined. Moreover, because the epithelial stem cells within a crypt segregate to daughter crypts when crypt fission occurs, an expansion of the stem cell number must accompany this reparative response. However, the factors that coordinate this complex process in diseases such as human inflammatory bowel disease have not been fully elucidated, and much remains unknown about the biologic consequences of chronic intestinal inflammation on the fate or proliferation of the stem cell population.
Inflammatory bowel disease is characterized by cycles of mucosal injury and ulceration, followed by epithelial regeneration and restoration of normal epithelial architecture and function. In several mouse models of inflammatory bowel disease, alterations of epithelial function have been implicated in the pathogenesis of chronic inflammation [60]. In general, intestinal inflammation is associated with significant upregulation of pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-8, IL-12 and tumor necrosis factor (TNF)-, along with other mediators and growth factors, such as cyclo-oxygenase (COX)-2, basic fibroblast growth factor (bFGF), hepatocyte growth factor, and vascular endothelial growth factor [60]. Expression of these inflammatory mediators is regulated by activation of nuclear factor-B (NF-B). NF-B is a key coordinator of innate immunity and inflammation and has emerged as an important endogenous tumor promoter [61, 62]. Crohn's ileitis is also associated with a reduced expression of Tcf-4, which regulates Paneth cell differentiation, leading to defects in innate immunity [63].
Expansion of the proliferative zone, increased crypt branching, and changes in the normal patterns of cellular differentiation have been documented in human inflammatory bowel disease [60], suggesting that the pathways regulating the relationship between cellular replication and epithelial differentiation have been altered in these diseases. Although it is clear that the intestinal epithelium responds to inflammation and mucosal injury by initiating a regenerative response, the specific effects inflammation may have on the in vivo turnover of epithelial stem cells or progenitor cells, or the way in which the inflammatory milieu may perturb normal epithelial differentiation and/or function remain obscure. Similarly, a number of cytokines, growth factors and other mediators including TNF-, transforming growth factor (TGF)3, trefoil factor-3 (TFF3), IL-1, IL-11, COX1/2, bFGF, FGF-7, and FGF-10 associated with intestinal inflammation or injury can induce increase in crypt epithelial stem cell survival when exogenously administered before radiation [64, 65]. However, more work is needed to understand how enhanced expression of one or more of these peptides, as a consequence of ileal inflammation, directly affects epithelial stem cells or differentiation of progenitor cells.
The radiosensitivity of the small intestine is primarily a function of rapidly dividing progenitor cells derived from epithelial stem cells near the base of intestinal crypts. Although crypt epithelial cells are extremely sensitive to radiation-induced apoptosis, there is little to no apoptosis in the villi. Doses as low as 0.01 to 1.0 Gy induce apoptosis within the lower crypt. Peak apoptosis is observed between 3 and 6 h post-irradiation [6567]. However, at higher doses (>8 Gy), a second apoptotic wave occurs 24 h post-irradiation. After severe irradiation, epithelial cell loss at the villus tips creates an imbalance between epithelial production and turnover, resulting in villi shortening and disruption of the mucosal barrier if all or most of the crypt stem cells die. However, if a single stem cell survives in the crypt region, regenerative crypts will appear within 3 to 4 days, and crypt-villi architecture will be restored within 6 to 8 days. The balance between the rate and extent of crypt-villi regeneration, which depends on the stem cell and the pathologic consequences of denuding the epithelial covering from the small intestine, is a major determinant of survival in the early period after acute radiation exposure.
The possible relationship between the quiescent and the actively cycling nature of the ISCs needs to be further explored. Moreover, it is critical to understand the genetic elements that determine stem cell fate and the basis by which regeneration occurs in order to better understand stem cell plasticity and the contribution made by the stem cell compartment to malignant disease. It is hoped that future studies in this area will provide a better platform to develop therapies to regenerate damaged intestinal epithelia as seen after radiation injuries or inflammatory bowel disease (eg, Crohn's disease).
This work was partially supported by National Institutes of Health Grant R01 CA131413 (to SU) from the NCI.
Disclosure No potential conflict of interest relevant to this article was reported.
Papers of particular interest, published recently, have been highlighted as:
Of importance
Of major importance
Read more:
- Adult Stem Cells: What They Are and What They Do - February 6th, 2025
- What Are Adult Stem Cells and Are They Right for You? - February 6th, 2025
- Stem Cell Program | Adult Stem Cells - Boston Children's Hospital - February 6th, 2025
- Different Types Of Stem Cells: Embryonic Vs. Adult ... - January 17th, 2025
- Rejuvenation of Aging Adult Stem Cells to Improve their Regenerative Potential - Frontiers - January 13th, 2025
- Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis - Business... - December 22nd, 2024
- What Are Stem Cells? Biomedical Beat Blog National Institute of ... - November 29th, 2024
- TVHS opens stem cell processing lab to expand biotherapies | VA Tennessee Valley health care | Veterans Affairs - Veterans Affairs - November 8th, 2024
- Understanding Mature Tissue or Organ Stem Cells and Their Clinical ... - November 8th, 2024
- Biology of stem cells: an overview - PMC - PubMed Central (PMC) - October 30th, 2024
- New government tech deals boost the business of cancer detection - GOV.UK - October 11th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Yahoo News UK - October 11th, 2024
- Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: a narrative review - Frontiers - September 26th, 2024
- Breakthrough technique may help speed understanding, treatment of MD, ALS - Harvard Gazette - September 14th, 2024
- Rostock University Explores Use of Stem Cells for Meat Cultivation with Help from Innocent Meat - vegconomist - the vegan business magazine - August 12th, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Targeting the stem cell niche micro-environment as therapeutic strategies in aging - Frontiers - June 28th, 2024
- International trial introduces another curative option for sickle cell disease - EurekAlert - June 28th, 2024
- HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation - Frontiers - June 28th, 2024
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and... - June 21st, 2024
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - June 21st, 2024
- Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - June 21st, 2024
- Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer - June 21st, 2024
- API and the University of Alberta Break Ground in Edmonton on Canada’s Largest Manufacturing Facility for Critical Medicines - June 21st, 2024
- Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems - June 21st, 2024
- Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform - June 21st, 2024
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog... - June 21st, 2024
- Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting - June 21st, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - June 21st, 2024
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran - June 21st, 2024
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’... - June 21st, 2024
- Radiopharm Receives Strategic Investment for up to A$18 million - June 21st, 2024
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee - June 21st, 2024
- Trading by management and close relations of management - June 21st, 2024
- Major shareholder announcement - June 21st, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 21st, 2024
- Nature retracts highly cited 2002 paper that claimed adult stem cells could become any type of cell - Retraction Watch - June 19th, 2024
- Shares of Biotech MicroCap Rip on Licensing Talks - The Globe and Mail - June 15th, 2024
- Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 - May 23rd, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23rd, 2024
- Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist... - May 23rd, 2024
- Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus... - May 23rd, 2024
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 - May 23rd, 2024
- New York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of... - May 23rd, 2024
- Syneos Health Leaders Recognized as PM360 ELITE 100 Award Recipients - May 23rd, 2024
- Kane Biotech Announces First Quarter 2024 Financial Results - May 23rd, 2024
- Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast - May 23rd, 2024
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - May 23rd, 2024
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 - May 23rd, 2024
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - May 23rd, 2024
- Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - May 23rd, 2024
- Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024 - May 23rd, 2024
- Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences - May 23rd, 2024
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - May 23rd, 2024
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual... - May 23rd, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
Recent Comments